Table A2.

Combination therapy in 3 months preceding control assessment—All respiratory medications (n = 280 participants).

Medication Combination	Frequency n (%)
(ICS + LABA) (SABA)	88 (31.4)
(ICS + LABA)	77 (27.5)
(SABA)	25 (8.9)
(ICS + LABA) (SABA)(LAMA)	22 (7.9)
(ICS + LABA) (LAMA)	14 (5.0)
(ICS)	6 (2.1)
(ICS + LABA) (Cromone)	4 (1.4)
(ICS) (ICS + LABA) (LAMA)	3 (1.1)
(ICS + LABA) (SABA) (SAMA)	3 (1.1)
(LAMA)	3 (1.1)
(SABA) (LAMA)	3 (1.1)
(ICS) (ICS + LABA) (SABA)	2 (0.7)
(ICS) (LABA)	2 (0.7)
(ICS) (SABA)	2 (0.7)
(ICS) (SABA) (LAMA + LABA)	2 (0.7)
(LAMA + LABA + ICS)	2 (0.7)
(SABA) (LAMA + LABA)	2 (0.7)
(SABA) (LAMA + LABA + ICS)	2 (0.7)
(ICS) (ICS + LABA)	1 (0.4)
(ICS) (ICS + LABA) (SABA) (LAMA)	1 (0.4)
(ICS) (ICS + LABA) (SABA) (LAMA) (LAMA + LABA)	1 (0.4)
(ICS) (LABA) (SABA) (LAMA)	1 (0.4)
(ICS) (LAMA + LABA)	1 (0.4)
(ICS) (SABA) (THEOPH)	1 (0.4)
(ICS + LABA) (LAMA) (LAMA + LABA)	1 (0.4)
(ICS + LABA) (LTRA)	1 (0.4)
(ICS + LABA) (MONOAB)	1 (0.4)
(ICS + LABA) (Cromone) (LAMA + LABA)	1 (0.4)
(ICS + LABA) (Cromone) (SABA)	1 (0.4)
(ICS + LABA) (Cromone) (SABA) (LAMA)	1 (0.4)
(ICS + LABA) (SABA) (LAMA)(LAMA + LABA + ICS)	1 (0.4)
(ICS + LABA) (SABA) (LAMA) (SAMA)	1 (0.4)
(ICS + LABA) (THEOPH) (LAMA)	1 (0.4)
(LAMA + LABA)	1 (0.4)
(LTRA) (SABA) (LAMA + LABA + ICS)	1 (0.4)
(SABA) (SAMA) (LAMA + LABA + ICS)	1 (0.4)